Last week, you might have seen that biote Corp. (NASDAQ:BTMD) released its third-quarter result to the market. The early response was not positive, with shares down 5.6% to US$2.71 in the past week. It looks like a credible result overall – although revenues of US$48m were what the analysts expected, biote surprised by delivering a (statutory) profit of US$0.22 per share, an impressive 371% above what was forecast. This is an important time for investors, as they can track a company’s performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Taking into account the latest results, biote’s five analysts currently expect revenues in 2026 to be US$198.4m, approximately in line with the last 12 months. Statutory earnings per share are expected to crater 65% to US$0.32 in the same period. Before this earnings report, the analysts had been forecasting revenues of US$201.9m and earnings per share (EPS) of US$0.34 in 2026. So it looks like there’s been a small decline in overall sentiment after the recent results – there’s been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts.
See our latest analysis for biote
The average price target fell 5.6% to US$4.61, with reduced earnings forecasts clearly tied to a lower valuation estimate. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on biote, with the most bullish analyst valuing it at US$6.00 and the most bearish at US$3.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the biote’s past performance and to peers in the same industry. We would highlight that biote’s revenue growth is expected to slow, with the forecast 1.1% annualised growth rate until the end of 2026 being well below the historical 10% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 9.0% per year. So it’s pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than biote.
